Objective To evaluate the effect of Fuzheng Kang'ai Formula (扶正抗癌方, FZKA) plus
gefitinib in patients with advanced non-small cell lung cancer with epidermal growth factor …

Background Patients with advanced non-small cell lung cancer (NSCLC) harboring
mutations of the epidermal growth factor receptor (EGFR) gene respond well to the EGFR …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned …

PURPOSE Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor combined with
cytotoxic chemotherapy is highly effective for the treatment of advanced non–small-cell lung …

Purpose Patients with advanced non-small cell lung cancer (NSCLC) harboring a sensitive
epidermal growth factor receptor (EGFR) mutation have been shown to exhibit a marked …

Gefitinib is effective in treating advanced non-small cell lung cancer (NSCLC), especially in
Asian patients in whom the prevalence of epidermal growth factor receptor (EGFR) mutation …

Aim: Most patients (pts) with EGFR mutation-positive NSCLC respond to 1st-line EGFR
tyrosine kinase inhibitors, but later acquire resistance. The Phase III, double-blind IRESSA …

Introduction Although standard schedule of gefitinib was the administration of 250 mg tablet
every day, many patients need dose reduction because of toxicities. However, the efficacy of …

Purpose The aim of this retrospective study is to evaluate the impact on efficacy and safety
between epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) alone and …

Purpose: Gefitinib is a well known therapy for non-small-cell lung cancer (NSCLC). The
purpose of this study was to review clinical reports of gefitinib as maintenance therapy after …